Jazz Pharmaceuticals, shared on LinkedIn:
“News for U.S. media and investors:
The U.S. FDA has approved our HER2-targeted therapy as part of two first-line treatment regimens for adults with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA).
This approval reinforces our continued commitment to redefining care for difficult-to-treat cancers and marks an important milestone for people living with HER2+ GEA, who have historically faced significant unmet need.”
You can also read: FDA Approves Ziihera With and Without Tislelizumab Plus Chemotherapy for First-Line HER2-Positive Gastroesophageal Adenocarcinoma
